CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Sheng-Li Xue, MD
- Phone Number: 86-13328008851
- Email: slxue@suda.edu.cn
Study Contact Backup
- Name: Lei Yu, Ph.D
- Phone Number: 86-13818629089
- Email: ylyh188@163.com
Study Locations
-
-
-
Suzhou, China
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- Sheng-Li Xue, Ph.D
- Phone Number: 86-13328008851
- Email: slxue@suda.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with CD19 positive central nervous system B-cell acute lymphocytic leukemia
- ALT/ AST 《 3x normal
- Creatinine 《 3x normal
- Age:10-60.
- Signed informed consent
Exclusion Criteria:
- Active hepatitis B , hepatitis C or HIV infection
- Uncontrolled active infection
- Pregnancy or breast-feeding women
- Survival less than four weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
|
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The complete remission (CR) rate
Time Frame: Participants will be followed for the duration of the treatment, an expected average of 12 months
|
The safety of the humanized CD19 CAR-T cells treatment will be evalated and the maximum tolerated dose will be determined
|
Participants will be followed for the duration of the treatment, an expected average of 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sheng-Li Xue, Ph.D, The First Affiliated Hospital of Soochow University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UnicarTherapy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.